Opus Genetics, Inc.
IRD
$1.96
-$0.03-1.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.42M | 13.65M | 10.99M | 8.38M | 16.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.42M | 13.65M | 10.99M | 8.38M | 16.45M |
| Cost of Revenue | 30.43M | 30.50M | 27.35M | 24.27M | 18.77M |
| Gross Profit | -15.01M | -16.85M | -16.36M | -15.89M | -2.32M |
| SG&A Expenses | 22.35M | 19.94M | 18.21M | 14.19M | 13.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.29M | 49.95M | 45.07M | 37.86M | 31.53M |
| Operating Income | -36.87M | -36.30M | -34.07M | -29.47M | -15.08M |
| Income Before Tax | -58.28M | -58.62M | -57.53M | -27.19M | -14.09M |
| Income Tax Expenses | -- | -- | -- | -2.00K | 12.00K |
| Earnings from Continuing Operations | -58.28 | -58.62 | -57.53 | -27.19 | -14.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.28M | -58.62M | -57.53M | -27.19M | -14.11M |
| EBIT | -36.87M | -36.30M | -34.07M | -29.47M | -15.08M |
| EBITDA | -36.84M | -36.28M | -34.07M | -29.47M | -15.07M |
| EPS Basic | -1.80 | -1.99 | -2.04 | -1.09 | -0.54 |
| Normalized Basic EPS | -0.55 | -0.67 | -0.70 | -0.68 | -0.34 |
| EPS Diluted | -1.81 | -1.99 | -2.04 | -1.09 | -0.55 |
| Normalized Diluted EPS | -0.55 | -0.67 | -0.70 | -0.68 | -0.34 |
| Average Basic Shares Outstanding | 153.77M | 116.22M | 106.85M | 99.49M | 94.79M |
| Average Diluted Shares Outstanding | 153.77M | 116.22M | 106.85M | 99.49M | 95.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |